Welcome toBrown Retina Institute
Dr. Brown participates in the Centers for Medicare and Medicaid Quality Payment Program. The goal is to improve the quality of care delivered to all Medicare beneficiaries.
Click here for more information.
We are committed to providing the best retina care . We do this by providing state-of-the-art retina diagnosis and treatment in a compassionate, caring environment. Our patient centered approach is practiced by everyone in the office. We will always strive to treat you with highest respect and fairness. In addition to treating your condition, we will take the time to explain your diagnosis, treatment plan and future course.
Located in San Antonio, Texas, Dr. Jeremiah Brown is a nationally recognized retina specialist, graduate of Harvard University, author, researcher and father. He is a bilingual, board certified ophthalmologist who has been awarded the American Academy of Ophthalmology Achievement Award. Dr. Brown served with distinction as a vitreoretinal surgeon in the US Army and was awarded the Army Meritorious Service Award. Dr. Brown specializes in many areas, including:
We look forward to having the opportunity to meet with you, discuss your condition and work with you in planning your care.
Call to schedule an appointment today.
Dr. Brown Speaks Spanish
Dr. Brown will be presenting the latest revolutionary news on macular degeneration, care and treatment at the upcoming Foundation Fighting Blindness conference in San Antonio. The lecture will be held at the UT Health Science Center, Academic Learning Center, 7703 Floyd Curl Drive, San Antonio, 78229 at 9:00 a.m. on January 27, 2018.
In April 2017, Lucentis received FDA approval for use in all patients with diabetic retinopathy. Previously, Lucentis could be used in patients with diabetic retinopathy, only they also had diabetic macular edema. The Rise and Ride Clinical Trials demonstrated that not only does Lucentis help to improve macular edema, it also can reverse the progression of retinopathy in up to 38% of patients. Now all patients with diabetic retinopathy can receive this beneficial treatment when appropriate. Brown DM, et al; RISE and RIDE Research Group. Ophthalmology. 2013;120:2013-2022.